Hematology department

• Hematologists
  • Pr Nathalie MEULEMAN, Head of Department
  • Pr Virginie DE WILDE, Head of Department (associated)
  • Dr Fabio ANDREOZZI
  • Pr Samantha BENGHIAT
  • Dr Sarah BUNTINX
  • Dr Martin COLARD
  • Dr Julie DALLEMAGNE
  • Pr Philippe LEWALLE
  • Dr Marie MAEREVOET
  • Dr Fulvio MASSARO
  • Dr Ornella RIZZO
  • Dr Adriano SALAROLI
  • Dr Chloé SPILLEBOUDT
  • Dr Marie VERCRUYSSEN
  • Pr Sebastian WITTNEBEL
  • Dr Alice WOLFROMM
     
• Consultants
  • Pr Dominique BRON
  • Dr Axelle GILLES
  • Dr Françoise LE MOINE
  • Pr Serge MOTTE

For the full team, see below

Hospitalisation
With a capacity of 70 beds, hospitalisation is divided into 4 principal care units:

• The sterile unit (B14) with 18 beds:
  • Acute leukaemias  
  • Medullary aplasia
  • Allografts
• The conventional unit (B13) with 22 beds:
  • Autografts
  • Semi-intensive chemotherapies
  • Treatment with CAR-T cell therapy
  • Treatment with immunotherapies and targeted therapies
  • Monitoring of administration of bispecific antibodies
  • Post-chemotherapy complications
• The general haematology unit (18 beds) at the Erasmus site
  • Treatment centre for diseases of red blood cells
  • Assessment requiring hospitalisation
  • Treatment of  non-cancerous haematologies
• The Day Hospital with 40 beds, 4 of them dedicated to cytapheresis techniques and 10 to outpatient haematological treatment.

The consultations

• The medical and paramedical team (psychologists, haematology coordinating nurses, dieticians, physiotherapists, beauty care) welcome you for consultations to monitor and treat your pathology. 
   
  • Making an appointment :
    • Tel : +32 (0)2 541 36 84 
    • Email : accueil.hematologie@hubruxelles.be 
  • Finding an expert : click here

Cytapheresis unit (clik here)
With 4 beds, this unit harvests blood elements and administers certain treatment

• Harvesting of autologous and anogeneic blood cells for transplants 
• Harvesting of blood cells
• Harvesting of lymphocytes for post-allograft administration or with a view to preparing treatment with CAR-T cells or gene therapy 
• In certain specific situations:  removal of excess red corpuscles (erythropheresis) or platelets
•  Plasmapheresis
• Treatment by photopheresis
• Infusion of haematopoetic stem cells and other cell products 

Clinical research unit (see the section below)

Cell therapy unit (clik here)

1. Pathologies treated in the department
   • Lymphomas (non-Hodgkin’s lymphoma and Hodgkin’s lymphoma)
   • Myeloma and similar diseases ( POEMS syndrome, gammopathies of clinical significance)
   • Amyloidosis
   • Chronic lymphoid leukaemia
   • Myeoproliferative syndrome (chronic myeloidic leukaemia, Vaquez disease, essential thrombocytemia, myelofibrosis, other rare myeloproliferative diseases)   
   • Myelodysplasic syndrome
   • Acute leukaemias
   • Treatment centre for rare haematological diseases
      
   • Make an appointment :
     • Tel : +32 (0)2 541 36 84 
     • Email : accueil.hematologie@hubruxelles.be
        
2. Specific treatment and procedures
   • Cytapheresis and photophoresis
   • Chemotherapies
   • Targeted therapies
   • Immunotherapies (monoclonal antibodies, immunomodulators) 
   • Transplant of hamatopoietic cells
   • Autograft
   • Allograft
   • Treatment with CAR-T cells
   • Treatment in the framework of clinical trials

The Haematology Department is recognised as:

A European expert centre for several rare diseases (European Reference Network (ERN:  https://www.ern-rnd.eu/)) : 

• Acute promyelocytic leukaemia: Dr Wittnebel / Dr Andreozzi
• Acute lymphoblastic leukaemia: Dr Buntinx / Dr Salaroli
• Amyloidosis : Professor Meuleman / Dr Rizzo / Dr Vercruyssen
• Burkitt’s lymphoma : Dr Massaro / Professor De Wilde
• T lymphoma: Dr Wolfromm / Dr Maerevoet
• Cutaneous lymphoma: Dr Maerevoet/ Dr Wolfromm / Dr De Vicq
• Mantle cell lymphoma: Professor De Wilde / Dr Massaro
• Cerebral  lymphoma:  Professor De Wilde / Dr Vercruyssen

Centre Joint Accreditation Committee ISCT-Europe & EBMT:                                                 

• Cell immunotherapy (CAR-T cells) : Dr Massaro and Dr Andreozzi 
• Cytapheresis: Dr Salaroli / Dr Dallemagne  
• Related and non-related allogenic transplants and haploidentical research
• Allogenic transplants in sickle cell disease (Click here : Erasme site)

Teaching is given at all levels of training: to students of medicine, in BioMed BACH3, to cancer nurses, to Master Classes at the EHA, to generalists, to doctors during specialisation, to paramedics, to the general public.  

All members of the multidisciplinary team are involved on a day-to-day basis in teaching and the transmission of our expertise and passion for haematology. 

Fundamental research
The Jules Bordet Institute Clinical Cell Therapy Research Laboratory (LTCC) is dedicated to fundamental and translational research in the fields of cell therapy related to haematology and immunology.
For further information:  https://www.bordet.be/en/clinical-cellular-therapy-research-laboratory-ltcc

Clinical research
Clinical research is vital for medical progress, making it possible to study the effectiveness and also the safety of new treatments. In the course of your treatment pathway you may have the option to take part in a clinical trial. 

The H.U.B’s  Clinical Haematology Research Department has grown over the years and today has 7 clinical research associates. They work in close cooperation with the medical team to enable patients to have access to the most innovative treatment.

Clinical trials at the Jules Bordet Institute cover the majority of malignant haemopathies (leukaemias, lymphomas, myelomas, myeloproliferative syndromes, myelodysplastic syndrome). In some cases these are based on techniques and treatment such as transplants or new immunotherapies (bispecific antibodies,  CAR-T cells).

There is never any obligation to participate  in a clinical trial, but they do permit access to new treatment and help achieve further progress in research. Participants are monitored very closely by a specialised medical team. 

Clinical trials play a vital role in discovering new treatment and improving care for present and future patients